Clinical Trial Detail

NCT ID NCT02535247
Title Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fox Chase Cancer Center
Indications

peripheral T-cell lymphoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.